NBIX Stock Analysis: Buy, Sell, or Hold?
NBIX - Neurocrine Biosciences Inc
$128.32
-4.10 (-3.10%)
▼
5d:
+0.5%
30d:
-1.78%
90d:
-12.56%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 04, 2026
Smart Money Accumulation
NBIX is down 6.6% this week, but smart money is accumulating calls. Top strike: $120 2026-05-15 with 308 OI. Call ratio: 88% View Scanner →
Strength: 7.1/10
Get Alerted When NBIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NBIX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: NBIX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$259.96
Based on 13.1% avg growth
INTRINSIC VALUE TODAY
$161.41
20.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NBIX is currently trading at $128.32, which is considered oversold relative to its 30-day fair value range of $128.36 to $131.57. The stock's valuation (Forward PE: 13.2) is in line with its historical norms (14.6). Remarkably, the market is currently pricing in an annual earnings decline of 3.2% over the next few years. This pessimistic expectation contrasts with the company's recent 47.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NBIX is in a strong downtrend. The price is currently testing key support at $125.11. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $178.04 (+38.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBIX is in a strong downtrend. The price is currently testing key support at $125.11. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $178.04 (+38.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$128.36 -
$131.57
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 38.7% below Wall St target ($178.04)
Fair Price Analysis
30-Day Fair Range
$128.36 -
$131.57
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$7.19
(5.6%)
Support & Resistance Levels
Support Level
$125.11
Resistance Level
$133.05
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.20
Wall Street Target
$178.04
(+38.7%)
Revenue Growth (YoY)
28.3%
Earnings Growth (YoY)
47.7%
Profit Margin
16.7%
Valuation Discount vs History
-3.2% cheaper
PE vs Historical
13.2 vs 14.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.2%
(market-implied from PE analysis)
1-Year Target
$124.21
(-3%)
2-Year Target
$120.24
(-6%)
3-Year Target
$116.39
(-9%)
3-Yr Target (if PE normalizes)
(PE: 13→15)
$128.73
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 22.1%)
$396.77
(+209%)
Base:
(SPY PE: 13.2, Growth: 22.1%)
$233.83
(+82%)
Bear:
(PE: 11.2, Growth: 22.1%)
$198.76
(+55%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 27.34 | Current EPS (TTM): $4.67
Bull Case
$280.90
(+121%)
Analyst growth 100.0%, PE expands to 30.1
Base Case
$255.36
(+101%)
Market implied 100.0%, PE stable at 27.3
Bear Case
$86.82
(-32%)
Severe decline -20.0%, PE contracts to 23.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.2 to 14.6
Stabilization Target:
$141.92
(+10.6%)
PE Expansion Potential:
+10.6%
Share & Embed Analysis
Last updated: March 30, 2026 7:04 AM ET
Data refreshes hourly during market hours. Next update: 8:04 AM
Data refreshes hourly during market hours. Next update: 8:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Kyle Gano
SELL
36400 shares
2026-01-16
Leslie V Norwalk
SELL
1190 shares
2025-12-16
Leslie V Norwalk
SELL
5000 shares
2025-12-15
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 58 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 58 HOLD |
Advanced NBIX Option Strategies
Professional options setups generated by AI based on today's NBIX price and gamma walls.
